Tocagen (NASDAQ:TOCA) issued its earnings results on Thursday. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.22, Morningstar.com reports. Tocagen had a negative return on equity of 77.46% and a negative net margin of 130,944.75%. The company had revenue of $18.01 million for the quarter, compared to analyst estimates of $2.01 million.
Shares of NASDAQ:TOCA traded up $0.78 during trading on Friday, reaching $13.08. 184,495 shares of the stock were exchanged, compared to its average volume of 165,769. The company has a quick ratio of 6.06, a current ratio of 6.06 and a debt-to-equity ratio of 0.56. Tocagen has a 1-year low of $7.52 and a 1-year high of $15.80. The firm has a market capitalization of $240.61 million, a price-to-earnings ratio of -4.92 and a beta of 2.84.
A number of equities analysts have recently weighed in on the company. Zacks Investment Research raised Tocagen from a “sell” rating to a “hold” rating in a research report on Saturday. ValuEngine raised Tocagen from a “hold” rating to a “buy” rating in a research report on Thursday, September 27th. BidaskClub raised Tocagen from a “hold” rating to a “buy” rating in a research report on Saturday, September 22nd. Chardan Capital assumed coverage on Tocagen in a research report on Thursday, August 30th. They set a “buy” rating and a $30.00 target price on the stock. Finally, B. Riley upped their target price on Tocagen from $15.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, September 20th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $20.75.
ILLEGAL ACTIVITY NOTICE: This story was first published by WKRB News and is owned by of WKRB News. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.wkrb13.com/2018/11/10/tocagen-toca-releases-earnings-results-beats-estimates-by-0-22-eps.html.
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
Read More: Understanding the different types of bonds
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.